Product Description: Rabeprazole-13C,d3 (sodium) (LY307640-13C,d3 (sodium)) is 13C labeled Rabeprazole (sodium). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C17 13CH17D3N3NaO3S
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Aly A M Shaalan, et al. Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels. Front Pharmacol. 2020 May 13;11:583./[3]Mengli Gu, et al. Rabeprazole Exhibits Antiproliferative Effects on Human Gastric Cancer Cell Lines. Oncol Lett. 2014 Oct;8(4):1739-1744./[4]Tara A Shea, et al. Identification of Proton-Pump Inhibitor Drugs That Inhibit <i>Trichomonas Vaginalis</i> Uridine Nucleoside Ribohydrolase. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1080-4.
Molecular Weight: 385.44
Research Area: Inflammation/Immunology;Cancer
Target: Apoptosis;Bacterial;Isotope-Labeled Compounds;Proton Pump
English
Deutsch
